New Paradigms In Colorectal Cancer – Part 1
Colon cancer, rectal cancer, colorectal cancer, bowel cancer; the name changes depending on where the malignancy originates, but diagnosis, genetics, and management have become more uniform and standardized. Read More...
January 31, 2023
Antibody Treatment Achieves Positive Results In A Dermatomyositis Trial
Dermatomyositis (DM) is a rare autoimmune disease that can occur at any age but is most common among people aged 40 to 60. The disease is also more common among women. Read More...
January 18, 2023
Daratumumab For AL Amyloidosis: Promising Results In A Tough Disease
AL amyloidosis causes devastating symptoms and typically carries a poor prognosis, with a high risk of organ damage and 30% of patients dying within the first year after diagnosis.1,2 The disease is also difficult to treat.3,4 Before 2021, there were no FDA-approved medications specifically for the condition. Read More...
January 18, 2023
Most Popular
Tumor Agnostic Treatments: A New Era In Oncology Drug Discovery
Tumor-agnostic treatments have come into prominence as a cutting-edge new method of treating cancer in an era where precision medicine has gained worldwide attention.
New Paradigms In Colorectal Cancer – Part 1
Colon cancer, rectal cancer, colorectal cancer, bowel cancer; the name changes depending on where the malignancy originates, but diagnosis, genetics, and management have become more uniform and standardized.
Antibody Treatment Achieves Positive Results In A Dermatomyositis Trial
Dermatomyositis (DM) is a rare autoimmune disease that can occur at any age but is most common among people aged 40 to 60.